ICOSLG and cancer: Our findings showed that MLKL was positively correlated with the expression of immune checkpoints such as PD1, PD-L1, PD-L2, and CTLA4 in most cancer types, except for ICOSLG, CD200, CEACAM1, HHLA2, and VTCN1 in BUC.